Are leukemic patient bone marrow mesenchymal stem cells malignant?.
- Author:
Zheng-Jun XIE
1
;
Deng-Ming HU
;
Wang-San-Bin
;
Bo YIN
;
Wei-Yang ZHENG
;
Bing XU
;
Xiao-Lan XU
;
Rong LIN
;
Ru FENG
;
Shu-Yun ZHOU
Author Information
1. Department of Hematology, Kunming General Hospital, Chengdu Military Area, Kunming 650032, China.
- Publication Type:Journal Article
- MeSH:
Bone Marrow Cells;
cytology;
Cells, Cultured;
Fusion Proteins, bcr-abl;
genetics;
Humans;
In Situ Hybridization, Fluorescence;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive;
genetics;
pathology;
Leukemia, Promyelocytic, Acute;
genetics;
pathology;
Mesenchymal Stromal Cells;
pathology;
Oncogene Proteins, Fusion;
genetics
- From:
Journal of Experimental Hematology
2007;15(5):913-918
- CountryChina
- Language:Chinese
-
Abstract:
The study was aimed to explore whether there are leukemic characteristics in the bone marrow mesenchymal stem cells (BMMSC) from leukemic patients as compared with normal controls. The mesenchymal stem cells from bone marrow of normal volunteers and patients with APL and CML were isolated, then cultured and proliferated in vitro. The morphology, growth curve and cell surface markers of two different sources mesenchymal stem cells were investigated for detecting whether the bone marrow mesenchymal stem cells derived from leukemia patients have the specific abnormal fusion gene of leukemia cells through fluorescent in situ hybridization. The results indicated that there was no significant difference between the mesenchymal stem cells derived from different subjects, the bone marrow mesenchymal stem cells derived from leukemia patients did not have the clonal malignant fusion gene as seen in the leukemia cells. Taken altogether, mesenchymal stem cells derived from leukemia patients had no biological differences as compared with those from normal volunteers, and no malignant clonal abnormality was found. It is concluded that mesenchymal stem cells derived from leukemia patients as an alternative vehicle may be used for assistant of autologous hematopoietic stem cell transplantation or cell therapy and gene therapy.
